1. Market Research
  2. > Biotechnology Market Trends
  3. > Janssen Biotech, Inc. - Product Pipeline Review - 2013

Janssen Biotech, Inc. - Product Pipeline Review - 2013

  • July 2013
  • -
  • Global Markets Direct
  • -
  • 30 pages

Janssen Biotech, Inc. - Product Pipeline Review - 2013

Summary

Global Markets Direct’s pharmaceuticals report, “Janssen Biotech, Inc. - Product Pipeline Review - 2013” provides data on the Janssen Biotech, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Janssen Biotech, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Janssen Biotech, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Janssen Biotech, Inc. - Brief Janssen Biotech, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Janssen Biotech, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Janssen Biotech, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Janssen Biotech, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Janssen Biotech, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Janssen Biotech, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Janssen Biotech, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Janssen Biotech, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Janssen Biotech, Inc. and identify potential opportunities in those areas.

Table Of Contents

Janssen Biotech, Inc. - Product Pipeline Review - 2013
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Janssen Biotech, Inc. Snapshot 5
Janssen Biotech, Inc. Overview 5
Key Information 5
Key Facts 5
Janssen Biotech, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Janssen Biotech, Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Janssen Biotech, Inc. - Pipeline Products Glance 11
Janssen Biotech, Inc. - Late Stage Pipeline 11
Janssen Biotech, Inc. Clinical Stage Pipeline Products 11
Phase I Products/Combination Treatment Modalities 11
Janssen Biotech, Inc. - Early Stage Pipeline Products 12
Preclinical Products/Combination Treatment Modalities 12
Discovery Products/Combination Treatment Modalities 13
Janssen Biotech, Inc. - Drug Profiles 14
AV-368 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
daratumumab 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
Drug For Osteoarthritis and Pulmonary Fibrosis 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
Narrow Spectrum Kinase Inhibitors 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
RON Program 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
VPI-2690-B 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
Janssen Biotech, Inc. - Pipeline Analysis 20
Janssen Biotech, Inc. - Pipeline Products by Therapeutic Class 20
Janssen Biotech, Inc. - Pipeline Products By Target 22
Janssen Biotech, Inc. - Pipeline Products by Route of Administration 23
Janssen Biotech, Inc. - Pipeline Products By Mechanism of Action 24
Janssen Biotech, Inc. - Recent Pipeline Updates 25
Janssen Biotech, Inc. - Dormant Projects 27
Janssen Biotech, Inc. - Locations And Subsidiaries 28
Head Office 28
Appendix 29
Methodology 29
Coverage 29
Secondary Research 29
Primary Research 29
Expert Panel Validation 29
Contact Us 30
Disclaimer 30

List of Tables

Janssen Biotech, Inc., Key Information 5
Janssen Biotech, Inc., Key Facts 5
Janssen Biotech, Inc. - Pipeline by Indication, 2013 7
Janssen Biotech, Inc. - Pipeline by Stage of Development, 2013 9
Janssen Biotech, Inc. - Monotherapy Products in Pipeline, 2013 10
Janssen Biotech, Inc. - Phase I, 2013 11
Janssen Biotech, Inc. - Preclinical, 2013 12
Janssen Biotech, Inc. - Discovery, 2013 13
Janssen Biotech, Inc. - Pipeline By Therapeutic Class, 2013 21
Janssen Biotech, Inc. - Pipeline By Target, 2013 22
Janssen Biotech, Inc. - Pipeline By Route of Administration, 2013 23
Janssen Biotech, Inc. - Pipeline Products By Mechanism of Action, 2013 24
Janssen Biotech, Inc. - Recent Pipeline Updates, 2013 25
Janssen Biotech, Inc. - Dormant Developmental Projects,2013 27

List of Figures

Janssen Biotech, Inc. - Pipeline by Indication, 2013 7
Janssen Biotech, Inc. - Pipeline by Stage of Development, 2013 9
Janssen Biotech, Inc. - Monotherapy Products in Pipeline, 2013 10
Janssen Biotech, Inc. - Pipeline By Therapeutic Class, 2013 20
Janssen Biotech, Inc. - Pipeline By Route of Administration, 2013 23
Janssen Biotech, Inc. - Pipeline Products By Mechanism of Action, 2013 24

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Glycoprotein 41 (gp41) - Pipeline Review, H2 2016

Glycoprotein 41 (gp41) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Glycoprotein 41 (gp41) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Glycoprotein 41 (gp41) - Pipeline Review, H2 2016’, provides in depth analysis on Glycoprotein 41 (gp41) targeted ...

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Pipeline Review, H2 2016

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Cellular Tumor Antigen p53 (Tumor Suppresso ...

Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Pipeline Review, H2 2016

Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Cytotoxic T Lymphocyte Protein 4 (Cytotoxic ...

Tetanus - Pipeline Review, H2 2016

September 2016 $ 2000

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.